pH |
Polymer-drug conjugates |
DOX |
4T1 |
Endocytosis pathway |
Lysosome & mitochondria |
1.9-fold higher |
2.5-fold lower |
Yes (Cas-3 activation) |
[81] |
Eph A10/TPP-DTX liposomes |
Docetaxel |
MCF-7 |
EphA 10 receptor mediated cell endocytosis |
Mitochondria |
0.14-fold lower |
Lower IC50 value |
Yes (highest Cas-3 and Cas-9 expression) |
[42] |
CTPP-CSOSA/celastrol micelles |
Celastrol |
MCF-7 |
Endocytosis pathway |
Mitochondria |
Dropped dramatically |
Lower IC50 value |
Yes (obvious increase in Cas-3 and Cas-9 activity) |
[43] |
HER-2/DOX DQAsomes |
DOX |
MCF-7 and MCF-7/ADR |
HER-2 peptide-mediated endocytosis |
Mitochondria |
A 6.9% decrease |
2.6-fold lower |
Yes (activated Cas-3 and Cas-9) |
[36] |
PEG-AIE-TPP micelle |
AIE-TPP |
MCF-7 |
Endocytosis pathway |
Mitochondria |
– |
– |
Yes |
[44] |
HPMA-MSN/DTX nanoparticles |
Docetaxel |
HeLa |
Endocytosis pathway |
Mitochondria |
Collapse |
A lower IC50 compared to pH7.4 |
Yes |
[45] |
TPP-Que-PEG nanoparticles |
Quercetin |
HeLa |
Endocytosis pathway |
Mitochondria |
Markedly decrease |
– |
Yes (improved activity of Cas-9 and Cas-3) |
[46] |
DSPE-KLA-DMA/PTX liposomes |
Paclitaxel |
A549 |
Macropinocytosis and clathrindependent endocytosis |
Mitochondria |
Reduce the most |
20-fold lower |
Yes (activated Cas-9 and −3) |
[47] |
PDPA/TPGS/DOX micelles |
DOX |
MCF-7/ADR |
Endocytosis pathway |
Mitochondria |
Reduced by 80% |
23-fold lower |
Yes |
[48] |
HHG2C18 liposomes |
Temsirolimus (CCI-779) |
A498 |
Endocytosis pathway |
Mitochondria |
– |
– |
– |
[49] |
CAT@S/Ce6-CTPP/DPEG |
Catalase |
4T1 |
Endocytosis pathway |
Mitochondria |
– |
– |
Yes |
[20] |
Redox |
Glucose-PEG-peptide-TPP-PAMAM-PTX conjugates |
Paclitaxel |
MCF-7/ADR |
Transporter-mediated pathways |
Mitochondria |
Destruction |
Strongest cytotoxicity |
– |
[78] |
TPP-oHA-S-S-Cur micelles |
Curcumin |
MDA-MB-231 |
CD44-mediated endocytosis |
Mitochondria |
– |
Better cellular cytotoxicity |
– |
[50] |
PLGA/C18-PEG-TPP/DLPE-S-S-mPEG/PTX nanoparticles |
Paclitaxel |
MCF-7 |
Macropinocytosis |
Mitochondria |
Decrease |
Higher cytotoxicity |
Yes (activated Cas-9 and −3) |
[51] |
TPP-PPA micelles |
PPA |
4T1 |
– |
Mitochondria |
Reduction |
Good cytotoxicity |
Yes (activated Cas-9 and −3) |
[76] |
Enzyme |
HA/PEG/berberine derivative nanodrugs |
Berberine derivative |
A549 |
CD44-mediated endocytosis |
Mitochondria |
The most significant decrease |
A much lower IC50
|
Yes (highest activities of Cas-9 and −3) |
[19] |
Non-isocyanate polyurethane-TPP/DOX nanocapsule |
DOX |
LN229 |
– |
Mitochondria |
– |
– |
– |
[52] |
TPP-peptide nanoassemblies |
TPP-peptide |
Saos2 |
Caveolae/lipid-raft mediated endocytosis |
Mitochondria |
– |
Higher cytotoxicity |
Yes |
[53] |
Light |
Perfluorooctyl bromide/IR780 liposomes |
IR780 |
4T1 |
Cell endocytosis |
Mitochondria |
– |
Higher cytotoxicity |
– |
[54] |
Iridium/Fe3O4 nanozyme |
Iridium |
Hela |
– |
Mitochondria |
Decreased markedly |
Higher cytotoxicity |
Yes |
[55] |
IR-780/DSPE-PEG2K-TPP liposomes |
IR-780; Lonidamine |
LL/2 |
Cell endocytosis |
Mitochondria |
Decrease |
Higher cytotoxicity |
Yes |
[56] |
AuNS-KLA-TPP/HA/DOX nanoparticles |
DOX |
SCC-7 |
CD44 receptor mediated endocytosis pathway |
Mitochondria |
Decrease |
Higher cytotoxicity |
Yes |
[58] |
TPP/Ce6/PEG-/FA-PEG-Pt@Au nanoparticles |
Ce6 |
MCF-7 |
Clathrin-mediated endocytosis pathway |
Mitochondria |
Loss |
Higher cytotoxicity |
Yes (activated Cas-3) |
[59] |
PPa-NGO-mAb nanodrug |
PPa |
U87-MG |
Integrin αvβ3 receptor mediated endocytosis |
Mitochondria |
– |
Higher cytotoxicity |
Yes |
[64] |
Yb/Tm/TiO2 nanoparticles |
Yb/Tm/TiO2
|
Hela |
– |
Mitochondria |
Loss |
Higher cytotoxicity |
Yes (activated Cas-9 and −3) |
[65] |
TPP-coumarin-Fe3O4 nanoparticles |
Fe3O4
|
Hela |
– |
Mitochondria |
– |
Hyperthermic cytotoxicity |
Yes |
[66] |
Cyt c aptamer-mesoporous silica-Au nanorods |
Au |
Hela |
– |
Mitochondria |
– |
Higher cytotoxicity |
Yes |
[67] |
Magnetic field |
DNA/PK-CP-SPION complexes |
DNA |
Hela |
– |
Mitochondria |
Obviously decreased |
Higher cytotoxicity |
Yes |
[69] |